EP1830873A4 - Glyponectine (adiponectine glycosylee) pour le traitement de maladies et d'etats pathologiques - Google Patents

Glyponectine (adiponectine glycosylee) pour le traitement de maladies et d'etats pathologiques

Info

Publication number: EP1830873A4
Authority: EP; European Patent Office
Prior art keywords: glyponectin; diseases; treatment; conditions; glycosylated adiponectin
Prior art date: 2004-12-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP05823200A

Other languages

German (de)

English (en)

Other versions

EP1830873A1 (fr

Inventor

Garth James Smith Cooper

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Protemix Corp Ltd

Original Assignee

Protemix Corp Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-10

Filing date

2005-12-08

Publication date

2008-04-02

2005-12-08 Application filed by Protemix Corp Ltd filed Critical Protemix Corp Ltd

2007-09-12 Publication of EP1830873A1 publication Critical patent/EP1830873A1/fr

2008-04-02 Publication of EP1830873A4 publication Critical patent/EP1830873A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP05823200A 2004-12-10 2005-12-08 Glyponectine (adiponectine glycosylee) pour le traitement de maladies et d'etats pathologiques Withdrawn EP1830873A4 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63504404P	2004-12-10	2004-12-10
PCT/NZ2005/000325 WO2006062422A1 (fr)	2004-12-10	2005-12-08	Glyponectine (adiponectine glycosylee) pour le traitement de maladies et d'etats pathologiques

Publications (2)

Publication Number	Publication Date
EP1830873A1 EP1830873A1 (fr)	2007-09-12
EP1830873A4 true EP1830873A4 (fr)	2008-04-02

Family

ID=36578169

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP05823200A Withdrawn EP1830873A4 (fr)	2004-12-10	2005-12-08	Glyponectine (adiponectine glycosylee) pour le traitement de maladies et d'etats pathologiques

Country Status (6)

Country	Link
US (1)	US20060128610A1 (fr)
EP (1)	EP1830873A4 (fr)
JP (1)	JP2008523057A (fr)
AU (1)	AU2005312435A1 (fr)
CA (1)	CA2590177A1 (fr)
WO (1)	WO2006062422A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA05002883A (es)	2002-08-20	2005-10-05	Protemix Corp Ltd	Formas de dosis y terapias relacionadas.
US20080261893A1 (en) *	2006-02-24	2008-10-23	Denise Barbut	Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
CA2680704A1 (fr) *	2007-03-12	2008-09-18	Sarentis Therapeutics, Inc.	Analgesie topique de la cornee utilisant des agonistes des recepteurs de la neurotensine et des associations synergiques de neurotensine sans retarder la cicatrisation des plaies
WO2008121009A1 (fr) *	2007-04-03	2008-10-09	Protemix Corporation Limited	Protéines d'adiponectine modifiées
US8017573B2 (en) *	2007-11-30	2011-09-13	Siemens Healthcare Diagnostics Inc.	Adiponectin receptor fragments and methods of use
WO2010010555A2 (fr) *	2008-07-21	2010-01-28	Transpharma Medical Ltd.	Système transdermique de délivrance prolongée d'incrétines et de peptides mimétiques de l'incrétine
TW201014598A (en) *	2008-08-27	2010-04-16	Otsuka Pharma Co Ltd	Agent for treating pulmonary disease
FR2944016B1 (fr) *	2009-04-02	2012-03-09	Isp Investments Inc	Nouveaux peptides anti-age activateurs du proteasome et compositions les contenant
FR2944015B1 (fr) *	2009-04-02	2012-03-09	Isp Investments Inc	Nouveaux peptides eclaircissants activateurs du proteasome et compositions les contenant
US9101618B2 (en) *	2011-12-15	2015-08-11	Tokyo Metropolitan Institute Of Medical Science	Method for treating and/or preventing neurodegenerative disease by adiponectin receptor agonist
RU2485939C1 (ru) *	2012-06-19	2013-06-27	Станислав Анатольевич Кедик	Офтальмологический препарат в виде глазных капель, содержащий дисульфирам и таурин
US20150258110A1 (en) *	2014-03-13	2015-09-17	Demerx, Inc.	Methods for acute and long-term treatment of alcohol dependence using ibogaine
US9561233B2 (en)	2014-03-13	2017-02-07	Demerx, Inc.	Use of ibogaine for the treatment of pain
US9592239B2 (en)	2014-09-12	2017-03-14	Demerx, Inc.	Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
US11304927B2 (en) *	2018-06-08	2022-04-19	Council Of Scientific And Industrial Research	Bioactive extract, fraction of Cassia occidentalis and formulation thereof for bone regeneration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1393739A1 (fr) *	2001-06-07	2004-03-03	Sankyo Company, Limited	Promoteur de generation de foie
WO2004096278A1 (fr) *	2003-04-28	2004-11-11	Sankyo Company, Limited	Activateur de la production d'adiponectine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5869330A (en) *	1995-06-05	1999-02-09	Whitehead Institute For Biomedical Research	DNA encoding a novel serum protein produced exclusively in adipocytes
FR2767135B1 (fr) *	1997-08-06	2002-07-12	Genset Sa	Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
PT1033134E (pt) *	1997-10-29	2007-07-11	Otsuka Pharma Co Ltd	Composições que inibem a proliferação de músculo liso e processo de diagonóstico da arteriosclerose
EP1127120B1 (fr) *	1998-11-04	2008-05-28	Serono Genetics Institute S.A.	Sequences d'adnc genomiques et completes d'apm1 humain specifique d'adipocytes et marqueurs bialleliques de ces derniers
US6579852B2 (en) *	2000-01-14	2003-06-17	Genset S.A.	OBG3 globular head and uses thereof for decreasing body mass
US6566332B2 (en) *	2000-01-14	2003-05-20	Genset S.A.	OBG3 globular head and uses thereof for decreasing body mass
EP1372726A4 (fr) *	2001-03-14	2004-04-21	Oklahoma Med Res Found	Procedes de reduction des graisses par administration d'adiponectine
US20060052292A1 (en) *	2001-12-21	2006-03-09	Maxygen Aps Maxygen Holdings, Ltd.	Adiponectin fragments and conjugates
EP1474445A4 (fr) *	2002-01-18	2007-02-21	Protemix Corp Ltd	Glyco-isoformes d'adiponectine, et utilisations correspondantes
WO2004056861A2 (fr)	2002-12-23	2004-07-08	Protemix Corporation Limited	Adiponectine et utilisations associees
JP2004315379A (ja) *	2003-04-11	2004-11-11	Suntory Ltd	発酵茶抽出物を主成分とするアディポネクチン上昇作用を有する組成物

2005
- 2005-12-08 AU AU2005312435A patent/AU2005312435A1/en not_active Abandoned
- 2005-12-08 JP JP2007545404A patent/JP2008523057A/ja active Pending
- 2005-12-08 EP EP05823200A patent/EP1830873A4/fr not_active Withdrawn
- 2005-12-08 CA CA002590177A patent/CA2590177A1/fr not_active Abandoned
- 2005-12-08 US US11/297,169 patent/US20060128610A1/en not_active Abandoned
- 2005-12-08 WO PCT/NZ2005/000325 patent/WO2006062422A1/fr active Application Filing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1393739A1 (fr) *	2001-06-07	2004-03-03	Sankyo Company, Limited	Promoteur de generation de foie
WO2004096278A1 (fr) *	2003-04-28	2004-11-11	Sankyo Company, Limited	Activateur de la production d'adiponectine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200480, Derwent World Patents Index; AN 2004-813826, XP002468454 *
See also references of WO2006062422A1 *

Also Published As

Publication number	Publication date
EP1830873A1 (fr)	2007-09-12
JP2008523057A (ja)	2008-07-03
WO2006062422A1 (fr)	2006-06-15
US20060128610A1 (en)	2006-06-15
AU2005312435A1 (en)	2006-06-15
CA2590177A1 (fr)	2006-06-15

Publication	Publication Date	Title
HRP20150175T1 (en)	2015-03-27	Means and methods for the treatment of tumorous diseases
IL178860A (en)	2013-04-30	Certain chemical entities, preparations and processes
HK1190084A1 (zh)	2014-06-27	用於預防和治療補體相關紊亂的多肽
IL179227A0 (en)	2007-03-08	Methods and reagents for the treatment of immunoinflammatory disorders
IL178142A0 (en)	2006-12-31	Methods of using and compositions comprising immunomodulatory compounos for the treatment and management of skin diseases or disorders
GB0404693D0 (en)	2004-04-07	Pharmaceutical preparations for the treatment of ocular surface and other disorders
ZA200607433B (en)	2009-09-30	Methods and compositions for the treatment of gastroin-testinal disorders
EP1450837A4 (fr)	2006-01-04	Recepteurs de l'interleukine-1 dans le traitement de maladies
IL178996A0 (en)	2007-03-08	Thienopyridinone compounds and methods of treatment
IL184934A0 (en)	2007-12-03	4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
IL182436A0 (en)	2007-07-24	Thienopyridinone compounds and methods of treatment
NO20051942D0 (no)	2005-04-20	Substituerte 4-cindazol-3-yl)fenoler som ostrogenreseptor-(ER) ligander og deres anvendelse ved behandling av inflammatoriske sykdommer
EP1487446A4 (fr)	2006-04-19	Heterocycles bicycliques pour le traitement des diabetes et d'autres maladies
PT1711070E (pt)	2016-02-15	Composição nutricional para melhorar o estado da pele e prevenir doenças de pele
EP1830873A4 (fr)	2008-04-02	Glyponectine (adiponectine glycosylee) pour le traitement de maladies et d'etats pathologiques
AU2003279442A8 (en)	2004-04-23	2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
ZA200609967B (en)	2008-06-25	Treating respiratory diseases with glycopyrrolate and analogues
AU2003286737A8 (en)	2004-06-07	Apparatuses and methods for the manufacture and placement of truss assemblies
EP1789047A4 (fr)	2010-03-17	Procede pour traiter des maladies au moyen de nalmefene et de ses analogues
ZA200806095B (en)	2009-06-24	Means and methods for the treatment of tumorous diseases
EP1720563A4 (fr)	2010-04-14	Procedes et compositions de traitement de l'inflammation
EP1805210A4 (fr)	2007-10-24	Nouveaux peptides et procédés pour le traitement de maladie inflammatoire
EP1715825A4 (fr)	2008-03-19	Methodes et dispositifs permettant d'eliminer les obstructions dans les voies aeriennes superieures
EP1740221A4 (fr)	2009-01-07	Procedes et compositions pour le traitement des maladies polykystiques
EP1810689A4 (fr)	2009-07-22	Agent prophylactique et/ou thérapeutique pour le traitement de diabètes

Legal Events

Date	Code	Title	Description
2007-08-10	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2007-09-12	17P	Request for examination filed	Effective date: 20070705
2007-09-12	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2008-03-19	DAX	Request for extension of the european patent (deleted)
2008-04-02	A4	Supplementary search report drawn up and despatched	Effective date: 20080229
2008-07-02	17Q	First examination report despatched	Effective date: 20080603
2009-10-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2010-10-20	19U	Interruption of proceedings before grant	Effective date: 20100713
2020-11-18	19W	Proceedings resumed before grant after interruption of proceedings	Effective date: 20210601
2021-06-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-09-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2021-10-20	18D	Application deemed to be withdrawn	Effective date: 20100701